CRDL
Price
$1.07
Change
-$0.01 (-0.92%)
Updated
Aug 29, 03:54 PM (EDT)
Capitalization
91.39M
81 days until earnings call
EOLS
Price
$7.56
Change
+$0.04 (+0.53%)
Updated
Aug 29, 03:57 PM (EDT)
Capitalization
486.43M
74 days until earnings call
Interact to see
Advertisement

CRDL vs EOLS

Header iconCRDL vs EOLS Comparison
Open Charts CRDL vs EOLSBanner chart's image
Cardiol Therapeutics
Price$1.07
Change-$0.01 (-0.92%)
Volume$300
Capitalization91.39M
Evolus
Price$7.56
Change+$0.04 (+0.53%)
Volume$100
Capitalization486.43M
CRDL vs EOLS Comparison Chart in %
Loading...
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRDL vs. EOLS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDL is a Hold and EOLS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (CRDL: $1.09 vs. EOLS: $7.52)
Brand notoriety: CRDL and EOLS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRDL: 120% vs. EOLS: 46%
Market capitalization -- CRDL: $91.39M vs. EOLS: $486.43M
CRDL [@Pharmaceuticals: Generic] is valued at $91.39M. EOLS’s [@Pharmaceuticals: Generic] market capitalization is $486.43M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRDL’s FA Score shows that 0 FA rating(s) are green whileEOLS’s FA Score has 0 green FA rating(s).

  • CRDL’s FA Score: 0 green, 5 red.
  • EOLS’s FA Score: 0 green, 5 red.
According to our system of comparison, CRDL is a better buy in the long-term than EOLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRDL’s TA Score shows that 5 TA indicator(s) are bullish while EOLS’s TA Score has 5 bullish TA indicator(s).

  • CRDL’s TA Score: 5 bullish, 5 bearish.
  • EOLS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, EOLS is a better buy in the short-term than CRDL.

Price Growth

CRDL (@Pharmaceuticals: Generic) experienced а -6.84% price change this week, while EOLS (@Pharmaceuticals: Generic) price change was +1.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.15%. For the same industry, the average monthly price growth was +68.06%, and the average quarterly price growth was +81.85%.

Reported Earning Dates

CRDL is expected to report earnings on Nov 18, 2025.

EOLS is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.15% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EOLS($486M) has a higher market cap than CRDL($91.4M). CRDL YTD gains are higher at: -14.844 vs. EOLS (-31.884). EOLS has higher annual earnings (EBITDA): -33.58M vs. CRDL (-39.94M). EOLS has more cash in the bank: 61.7M vs. CRDL (18.2M). CRDL has less debt than EOLS: CRDL (143K) vs EOLS (155M). EOLS has higher revenues than CRDL: EOLS (278M) vs CRDL (0).
CRDLEOLSCRDL / EOLS
Capitalization91.4M486M19%
EBITDA-39.94M-33.58M119%
Gain YTD-14.844-31.88447%
P/E RatioN/AN/A-
Revenue0278M-
Total Cash18.2M61.7M29%
Total Debt143K155M0%
FUNDAMENTALS RATINGS
CRDL vs EOLS: Fundamental Ratings
CRDL
EOLS
OUTLOOK RATING
1..100
582
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10071
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8791
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRDL's Valuation (66) in the null industry is in the same range as EOLS (92) in the Pharmaceuticals Major industry. This means that CRDL’s stock grew similarly to EOLS’s over the last 12 months.

EOLS's Profit vs Risk Rating (71) in the Pharmaceuticals Major industry is in the same range as CRDL (100) in the null industry. This means that EOLS’s stock grew similarly to CRDL’s over the last 12 months.

EOLS's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as CRDL (100) in the null industry. This means that EOLS’s stock grew similarly to CRDL’s over the last 12 months.

CRDL's Price Growth Rating (87) in the null industry is in the same range as EOLS (91) in the Pharmaceuticals Major industry. This means that CRDL’s stock grew similarly to EOLS’s over the last 12 months.

CRDL's P/E Growth Rating (100) in the null industry is in the same range as EOLS (100) in the Pharmaceuticals Major industry. This means that CRDL’s stock grew similarly to EOLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRDLEOLS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
84%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CRDL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EOLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FRIQX12.22N/A
N/A
Fidelity Advisor Real Estate Income M
BRXCX15.85N/A
N/A
MFS Blended Research Intl Eq C
AEGSX35.58N/A
N/A
Invesco International Value R6
WMKSX17.49N/A
N/A
WesMark Small Company Fund
MGKIX14.65N/A
N/A
Morgan Stanley Global Permanence I

CRDL and

Correlation & Price change

A.I.dvisor tells us that CRDL and ACB have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRDL and ACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRDL
1D Price
Change %
CRDL100%
-2.68%
ACB - CRDL
32%
Poorly correlated
+5.44%
EOLS - CRDL
29%
Poorly correlated
-0.79%
LNTH - CRDL
28%
Poorly correlated
-2.36%
OGI - CRDL
28%
Poorly correlated
+3.59%
SCYX - CRDL
25%
Poorly correlated
+1.76%
More

EOLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EOLS has been loosely correlated with PRGO. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if EOLS jumps, then PRGO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EOLS
1D Price
Change %
EOLS100%
-0.79%
PRGO - EOLS
44%
Loosely correlated
-0.54%
AMRX - EOLS
33%
Loosely correlated
+2.03%
LNTH - EOLS
33%
Poorly correlated
-2.36%
ALKS - EOLS
31%
Poorly correlated
-1.09%
HROW - EOLS
28%
Poorly correlated
+0.52%
More